Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 1, 2008, Pages 13-20

  Gioia, Giuseppe ^a   Benassi, Alberto ^a   Mohendra, Raghar ^a   Chowdhury, Khaza ^a   Masood, Iqbal ^a   Matthai, William ^a  

^a NONE   (United States)

Author keywords

BMS; DES; SVG

Indexed keywords

PACLITAXEL; RAPAMYCIN; TACROLIMUS;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; RESTENOSIS; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STENT; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; TIME FACTORS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 47549096848     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21599     Document Type: Article

References (22)

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349: 1315-1323.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med 2002;346:1773-1780.
4. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. Circulation 2004; 109:190-195.
5. Medina A, Suarez de Lezo J, Pan M, Delgado A, Segura J, Pavlovic D, Melián F, Romero M, Segura F, Hernández E, Ureña I, Herrador J. Sirolimus-eluting stents for treatment of in-stent restenosis: Immediate and late results. Tex Heart Inst J 2005; 32:11-15.
6. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005;293:165-171.
7. Serruys PW.Arterial revascularization therapies study part II: Sirolimus-eluting stents for the treatment of patients with multi-vessel de novo coronary artery lesions (ARTS II). Presented at the 2005 ACC 54th Annual Scientific Session, Orlando, FL, March 2005.
8. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
9. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109:2273-2278.
10. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, Mehran R, Russell ME, Stone GW; TAXUS-IV Investigators. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1186-1192.
11. Gupta N, Debsikdar J, Brodie BR. Drug-eluting stents vs. bare metal stents in patients with non-ST elevation myocardial infarction: Results from the STENT registry. Am J Cardiol 2004;94 (Supp16):11E.
12. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M, Airoldi F, Michev I, Sangiorgi MG, Carlino M, Vitrella G, Colombo A. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-795.
13. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double blind randomized controlled trial (E-SIRIUS). Lancet 2003;362: 1093-1099.
14. Gioia G, Matthai W, Benassi A, Rana H, Levite HA, Ewing LG. Outcomes of drug-eluting stent implantation compared to bare metal stent in patients with severe left ventricular dysfunction. Catheter Cardiovasc Interv 2006;67:775.
15. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts. J Am Coll Cardiol 2006;48:2423-2431.
16. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, Hofma S, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004; 16:230-233.
17. Price MJ, Sawhney N, Kao JA, Madrid A, Schatz RA, Teirstein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005;65:208-211.
18. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug eluting stents. J Am Coll Cardiol 2005;45:989-994.
19. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66:507-511.
20. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared to bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
21. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G, for the DELEYED RRISC Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. J Am Coll Cardiol 2007;50: 261-267.
22. Wilson BH, Humphrey AD, Cedarholm JD, Elliot CM, Harber RH, Kowalchuk GT, Rinaldi MS, Simonton CA III, Abstract. Drug-eluting stents are no better than bare metal in vein graft: Results from the strategy transcatheter evaluation of new therapies (STENT) group. J Am Coll Cardiol 2007;41B:2802-2803.